Medical Oncologist
Metastatic colorectal cancer
Cetuximab vs Bevacizumab — Which Drug and When
Both drugs are added to chemotherapy in metastatic colorectal cancer, but they work through completely different mechanisms and suit different patients. Your RAS test result and where the tumour started in the bowel are the two things that decide which one your oncologist will recommend.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Your RAS result is the first filter — Cetuximab works only if your tumour has no RAS mutation. Bevacizumab works regardless of RAS status.
- Tumour location also shapes the decision — Left-sided tumours tend to respond better to cetuximab. For right-sided disease, bevacizumab is usually preferred even when RAS is wild-type.
- Different side effects to plan for — Cetuximab commonly causes a skin rash and low magnesium. Bevacizumab can raise blood pressure and carries a small risk of blood clots.
- Biosimilars have changed the cost picture — Biosimilar versions of bevacizumab are widely available in India and substantially cheaper than the originator brand.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The main difference is your RAS test result. Cetuximab works only in RAS wild-type tumours and is preferred for left-sided disease. Bevacizumab works regardless of RAS status. Your oncologist will recommend one based on your biomarker result, where the tumour started in the bowel, and your overall fitness.
How do cetuximab and bevacizumab compare?
| Feature | Cetuximab (Erbitux) | Bevacizumab (Avastin) |
|---|---|---|
| Drug class | EGFR inhibitor — blocks a growth signal on the surface of cancer cells | VEGF inhibitor — blocks the signal that tumours use to grow new blood vessels |
| Required biomarker test | RAS testing (KRAS and NRAS) must confirm wild-type before use | No predictive biomarker test currently required |
| Who it suits | RAS wild-type disease, especially left-sided tumours | RAS mutant disease; also used in right-sided disease and where cetuximab is not suitable |
| Tumour side preference | Preferred for left-sided tumours (descending colon, sigmoid, rectum) | Right-sided or left-sided; first choice when RAS is mutant |
| Typical chemotherapy backbone | FOLFOX or FOLFIRI — IV chemotherapy every two weeks | FOLFOX, FOLFIRI, or CAPOX — every two to three weeks |
| Common side effects | Acneiform skin rash, dry skin, nail changes, low magnesium | High blood pressure, fatigue, protein in urine |
| Serious side effects to know | Severe infusion reaction (premedication given to reduce risk); rarely, lung inflammation | Arterial blood clot, bowel perforation (rare), wound healing impairment, bleeding |
| CNS activity in colorectal cancer | No established role in colorectal cancer that has spread to the brain | No established role in colorectal cancer that has spread to the brain |
| Biosimilars in India | Limited biosimilar options currently available | Multiple approved biosimilars available; substantially cheaper than originator |
| Indicative cost (India, 2026) | Higher per-cycle cost; fewer lower-cost options | Originator expensive; biosimilar options reduce cost significantly |
Why does where the tumour started in the bowel matter?
Left-sided colorectal tumours — those in the descending colon, sigmoid colon and rectum — tend to have a different molecular profile from right-sided tumours in the ascending colon and caecum.
NCCN and ESMO guidance both state that in RAS wild-type disease, EGFR inhibitors such as cetuximab offer greater benefit in left-sided disease. In right-sided disease, the benefit is less clear even when RAS is wild-type, and bevacizumab is generally preferred.
This is why your oncologist may ask specifically where in the bowel the original tumour was, even if it has since spread. That location still carries biological information that affects treatment choice.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What to confirm before your first infusion
- Ask your team what your RAS test showed — this result determines which drug is appropriate for you.
- If starting cetuximab: ask about premedication before your first infusion and when your magnesium levels will be checked.
- If starting bevacizumab: ask how your blood pressure will be monitored each cycle and what reading warrants a same-day call.
- Tell your team about any recent surgery or planned procedure — bevacizumab affects wound healing and timing matters.
- Ask which new symptoms in the first two weeks need a same-day call rather than waiting for your next appointment.
- Confirm when your response-assessment scan (usually a CT) is scheduled.
Terms your oncologist may use
- RAS wild-type
- Your tumour has no mutation in the RAS gene family. This is the result required before cetuximab can be considered.
- RAS mutant
- Your tumour carries a mutation in KRAS or NRAS. EGFR inhibitors such as cetuximab do not work in RAS mutant disease, and another approach is used.
- EGFR
- Epidermal growth factor receptor — a protein on the surface of some cancer cells that drives growth. Cetuximab binds and blocks this signal.
- VEGF
- Vascular endothelial growth factor — a signal that tumours use to grow new blood vessels. Bevacizumab blocks this signal, starving the tumour of its blood supply.
- Biosimilar
- A medicine shown to be highly similar to an approved biologic drug. Biosimilars go through regulatory approval and are a legitimate, often more affordable option — not the same as a generic tablet.
- FOLFOX / FOLFIRI / CAPOX
- Chemotherapy regimens used in colorectal cancer. Both cetuximab and bevacizumab are added to one of these backbones; neither is given alone.
Did you know?
In patients with RAS mutant colorectal cancer — which accounts for roughly half of all cases — cetuximab provides no benefit and is not indicated.
Giving it in that setting would expose the patient to side effects with no prospect of the intended effect. This is why biomarker testing before treatment is not optional: it is the reason the test exists.
Source: NCCN Guidelines for Colon Cancer and Rectal Cancer (current edition)
Explore 100 more Gastrointestinal & Liver Targeted Medicines topics
Drug Deep Dive: Cetuximab (Erbitux)
- Cetuximab (Erbitux): The Complete Patient Guide
- Cetuximab Infusion Day: Premedication, Duration and What to Expect
- Cetuximab Infusion Reactions: Why the First Dose Is Given Slowly
- Cetuximab Myths: 'The Worse the Rash, the Better' and Other Half-Truths
- Cetuximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Cetuximab Side Effects: The Complete List and Timeline
- Cetuximab Success Rate and Survival: An Honest Look at the Numbers
- Cetuximab With FOLFIRI, FOLFOX and Radiation
- Cetuximab in Colorectal vs Head and Neck Cancer: Different Roles
- Cetuximab in Elderly Patients and Those With Other Illnesses
- Cetuximab vs Bevacizumab in Colorectal Cancer: Which and When
- Diet and Nutrition While on Cetuximab
- Drug, Food and Supplement Interactions With Cetuximab
- Fertility, Pregnancy and Contraception on Cetuximab
- How Does Cetuximab Work? The Anti-EGFR Monoclonal Antibody Explained
- How Long Does Cetuximab Take to Work?
- How Long Will You Stay on Cetuximab?
- Low Magnesium on Cetuximab: Cramps, Fatigue and Monthly Testing
- Tests and Monitoring While You Are on Cetuximab
- The Cetuximab Rash: Severity, Treatment and Why It Predicts Response
- When Cetuximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Cetuximab? RAS Wild-Type Colorectal Cancer and Head and Neck Cancer
- Why Cetuximab Only Works in RAS Wild-Type, Left-Sided Tumours
- Will Insurance or a Government Scheme Pay for Cetuximab?
- Work, Travel and Daily Life on Cetuximab
Drug Deep Dive: Bevacizumab (Avastin)
- Avastin vs Biosimilar Bevacizumab in India: Cost and Safety
- Bevacizumab (Avastin and biosimilars): The Complete Patient Guide
- Bevacizumab Infusion Day: Premedication, Duration and What to Expect
- Bevacizumab Myths: 'It Dissolves Tumours' and Other Misconceptions
- Bevacizumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Bevacizumab Side Effects: The Complete List and Timeline
- Bevacizumab Success Rate and Survival: An Honest Look at the Numbers
- Bevacizumab With Chemotherapy: Which Combinations and Why
- Bevacizumab in Elderly Patients and Those With Other Illnesses
- Bevacizumab in Eye Disease vs Cancer: Same Drug, Very Different Dose
- Bleeding, Bowel Perforation and Wound Healing Risks on Bevacizumab
- Diet and Nutrition While on Bevacizumab
- Drug, Food and Supplement Interactions With Bevacizumab
- Fertility, Pregnancy and Contraception on Bevacizumab
- High Blood Pressure on Bevacizumab: Monitoring and Treatment
- How Does Bevacizumab Work? The Anti-VEGF Angiogenesis Inhibitor Explained
- How Long Does Bevacizumab Take to Work?
- How Long Will You Stay on Bevacizumab?
- Protein in Your Urine on Bevacizumab: What the Report Means
- Surgery While on Bevacizumab: The 28-Day Rule
- Tests and Monitoring While You Are on Bevacizumab
- When Bevacizumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Bevacizumab? Colorectal, Lung, Ovarian, Cervical and Brain Cancer
- Will Insurance or a Government Scheme Pay for Bevacizumab?
- Work, Travel and Daily Life on Bevacizumab
Drug Deep Dive: Lenvatinib (Lenvima)
- Blood Pressure Spikes on Lenvatinib: The Critical First Two Weeks
- Diarrhoea, Appetite Loss and Rapid Weight Drop on Lenvatinib
- Diet and Nutrition While on Lenvatinib
- Dose Reductions on Lenvatinib: Why Most Patients Need One
- Drug, Food and Supplement Interactions With Lenvatinib
- Fertility, Pregnancy and Contraception on Lenvatinib
- Hand-Foot Skin Reaction on Lenvatinib: Prevention and Relief
- How Does Lenvatinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Lenvatinib Take to Work?
- How Long Will You Stay on Lenvatinib?
- Lenvatinib (Lenvima, Lenvanix): The Complete Patient Guide
- Lenvatinib Myths: Side Effects, Dose Cuts and 'Giving Up'
- Lenvatinib Price in India: Brand, Generic and Monthly Cost
- Lenvatinib Side Effects: The Complete List and Timeline
- Lenvatinib Success Rate and Survival: An Honest Look at the Numbers
- Lenvatinib With Immunotherapy: The Combination Explained
- Lenvatinib for Radioactive-Iodine-Refractory Thyroid Cancer
- Lenvatinib in Elderly Patients and Those With Other Illnesses
- Lenvatinib vs Sorafenib for Liver Cancer: Which Comes First?
- Taking Lenvatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Lenvatinib
- When Lenvatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Lenvatinib? Liver, Thyroid, Kidney and Endometrial Cancer
- Will Insurance or a Government Scheme Pay for Lenvatinib?
- Work, Travel and Daily Life on Lenvatinib
Drug Deep Dive: Sorafenib (Nexavar)
- Blood Pressure, Rash and Hair Thinning on Sorafenib
- Diarrhoea on Sorafenib: Controlling It Without Stopping Treatment
- Diet and Nutrition While on Sorafenib
- Drug, Food and Supplement Interactions With Sorafenib
- Fertility, Pregnancy and Contraception on Sorafenib
- Hand-Foot Skin Reaction on Sorafenib: Prevention From Day One
- How Does Sorafenib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sorafenib Take to Work?
- How Long Will You Stay on Sorafenib?
- Sorafenib (Nexavar, Soranib): The Complete Patient Guide
- Sorafenib Myths: Dose Reduction, 'Last Resort' and Generic Quality
- Sorafenib Price in India: Brand, Generic and Monthly Cost
- Sorafenib Side Effects: The Complete List and Timeline
- Sorafenib Success Rate and Survival: An Honest Look at the Numbers
- Sorafenib With Cirrhosis: Why Child-Pugh Status Decides Eligibility
- Sorafenib With TACE and Other Liver-Directed Treatments
- Sorafenib in Elderly Patients and Those With Other Illnesses
- Sorafenib in Liver, Kidney and Thyroid Cancer: Three Different Uses
- Sorafenib vs Lenvatinib for Liver Cancer: Cost, Tolerability and Evidence
- Taking Sorafenib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sorafenib
- When Sorafenib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sorafenib? Liver, Kidney and Radioiodine-Refractory Thyroid Cancer
- Will Insurance or a Government Scheme Pay for Sorafenib?
- Work, Travel and Daily Life on Sorafenib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Can I have cetuximab if my RAS test came back mutant?
No. Cetuximab and other EGFR inhibitors do not work in RAS mutant disease — the mutation bypasses the pathway the drug targets. Giving it in that setting would expose you to side effects with no realistic prospect of benefit. Your oncologist will recommend a bevacizumab-based regimen instead, which works regardless of RAS status. If you are unsure what your test showed, ask your team for the result in writing.
Is one drug stronger than the other?
Neither drug is simply stronger. Each works through a different mechanism and in a different patient population. In the patients each drug is suited to, NCCN and ESMO guidance supports both as appropriate first-line choices alongside chemotherapy. Comparing them outside their indicated populations gives a misleading picture. The right drug for you is the one that matches your biomarker result and tumour location — not the one with the larger effect size in a study that may not include patients like you.
What does the skin rash from cetuximab mean?
The acneiform rash that cetuximab commonly causes appears on the face, chest and back, usually within the first two weeks. It is not an allergic reaction and is not a sign that the drug is harming you. ESMO clinical practice guidelines note an association between moderate rash and treatment response, though this is not reliable enough to use as a formal marker. Your team will advise on skincare. Tell them if the rash is severe, painful, or disrupting your sleep.
My blood pressure has gone up since starting bevacizumab. Is that serious?
High blood pressure is one of the most common effects of bevacizumab, and your team will monitor it at each cycle. In many patients it is managed with standard blood pressure medication and treatment continues. Report any reading that is clearly higher than your usual, any headache that comes alongside it, or any visual changes — those symptoms need a same-day call. Do not stop your infusions without telling your oncologist, but do not ignore a pressure that is climbing.
Can either drug treat colorectal cancer that has spread to the brain?
Neither cetuximab nor bevacizumab has an established role in colorectal cancer that has spread to the brain. Brain metastases from colorectal cancer are uncommon, and when they occur, treatment usually involves radiation to the brain rather than a change to the systemic drug. If you have been told the cancer has reached the brain, your oncologist will explain the plan for that separately. The drug being used for the disease elsewhere in the body may or may not change.
Is there a more affordable option for either drug?
For bevacizumab, yes — several biosimilars are approved and available in India, and they reduce the per-cycle cost significantly compared with originator Avastin. For cetuximab, the biosimilar landscape in India is more limited currently. Ask your team whether a biosimilar version is available for the drug you have been prescribed. Approved biosimilars are not inferior in safety or effectiveness, and using one is a clinically sound choice.